Stockreport

Keros Therapeutics to Present at the 66th American Society of Hematology Annual Meeting and Exposition

Keros Therapeutics, Inc. - common stock  (KROS) 
PDF LEXINGTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing [Read more]